Bafna Pharmaceuticals Q2 Results 2026: PAT ₹7 Cr, Revenue ₹48 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹48Cr
- Net profit
- ₹7Cr
- Margin
- 18%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Bafna Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for the quarter ended 30th September 2026: INR 4,766.56 Lakhs.
As stated in Bafna Pharmaceuticals Ltd's Q2 FY27 results statement · published 11 Nov 2026. Reported figures, not investment advice.
Based on Bafna Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from Operations for the quarter ended 30th September 2026: INR 4,766.56 Lakhs. Quarterly EBITDA: INR 755.11 Lakhs (calculated as Profit before tax INR 692.33 Lakhs + Finance cost INR 195.69 Lakhs + Depreciation INR 364.91 Lakhs - Other income INR 113.41 Lakhs).
From Bafna Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 11 Nov 2026.
How did Bafna Pharmaceuticals' revenue grow in the September 2026 quarter?
- Revenue from Operations for the quarter ended 30th September 2026: INR 4,766.56 Lakhs.
- Revenue from Operations for the quarter ended 30th September 2025: INR 3,546.82 Lakhs.
- Year-on-year revenue growth: INR 4,766.56 Lakhs vs. INR 3,546.82 Lakhs, approximately 34.4% increase.
What happened to Bafna Pharmaceuticals' margins in Q2 FY27?
See what Bafna Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
What capex is Bafna Pharmaceuticals planning?
See what Bafna Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Bafna Pharmaceuticals raising money or cutting debt?
See what Bafna Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Bafna Pharmaceuticals' order book?
See what Bafna Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Bafna Pharmaceuticals Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Bafna Pharmaceuticals Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 48 |
| Operating profit (EBITDA) | 9 |
| Operating margin | 18% |
| Profit before tax | 7 |
| Net profit (PAT) | 7 |
| EPS (₹) | 2.89 |
Source: Bafna Pharmaceuticals Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹27 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsRevenue ₹3770 Cr · PAT ₹1,127 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Bal Pharma (Q2 FY27)
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…
- Quest Laboratories (Q2 FY27)
Revenue from operations for the half year ended 30th September 2026 is ₹5,533.55 lakhs, compared to ₹4,880.48 lakhs for the half year ended 30th September…
- Haleos Labs Limited (Q2 FY27)
1,036.03 Lakhs (~13.3% growth). Key results statement takeaways from Haleos Labs Limited's Q2 FY27 results statement — and how it ranks against sector peers.
- Curis Lifesciences (Q2 FY27)
2790.89 lakh for the quarter ended 30.09.2025 (standalone), indicating a year-on-year increase of approximately 32.8%. Key results statement takeaways from Curi
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Bafna Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Bafna Pharmaceuticals Ltd Q2 FY27 results?
Revenue from Operations for the quarter ended 30th September 2026: INR 4,766.56 Lakhs. Quarterly EBITDA: INR 755.11 Lakhs (calculated as Profit before tax INR 692.33 Lakhs + Finance cost INR 195.69 Lakhs + Depreciation INR 364.91 Lakhs - Other income INR 113.41 Lakhs).
What is Bafna Pharmaceuticals Ltd share price analysis?
Bafna Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 145.0 with a market cap of ₹1,130 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Bafna Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.